Did you attend the SIDS Lecture?

Yes

No (Click Continue at the end of this page to go to the next section)

SIDS is: (Value: 1 point)

The sudden and unexplained death of an infant younger than one year of age

Caused by vomiting and/or choking

Determined only after an autopsy, an examination of the death scene, and a review of the infant’s and family’s clinical histories

Both A and C

The triple-risk model describes: (Value: 1 point)

The most dangerous environmental stressors associated with SIDS

The convergence of three conditions that may lead to the death of an infant from SIDS

The genetic mutations linked to SIDS

The three most critical developmental periods associated with SIDS

Each of the following is a major modifiable factor that puts infants at higher risk of SIDS, except: (Value: 1 point)

Stomach sleeping for naps and at night

Soft sleep surfaces and loose bedding

Tummy Time

Maternal smoking during pregnancy

Since 1992, SIDS rates in the United States have: (Value: 1 point)

Increased in all populations

Remained constant

Increased among Hispanic infants, but declined in all other populations

Declined in all populations

SIDS rates remain disproportionately high in which of the following ethnic groups: (Value: 1 point)

Hispanics

African Americans

American Indians/Alaska Natives

Both B and C

Which of the following constitutes a safe sleeping environment for an infant: (Value: 1 point)

A firm mattress with stuffed toys surrounding the perimeter

Soft sleep surfaces

A firm mattress, free of loose bedding and stuffed toys

Loose bedding, such as quilts and comforters

Tummy Time is appropriate when: (Value: 1 point)

An infant is awake but drowsy

An infant is awake and supervised

An infant is asleep

An infant is unsupervised

nurses speak to parents and caregivers about SIDS, it is important that their messages: (Value: 1 point)

Be detailed

Include statistics

Be clear and culturally appropriate

Include medical terminology

Among parents and caregivers, common reasons for not complying with SIDS risk-reduction recommendations include: (Value: 1 point)

Relatives recommend the prone position

Concern about flattened skull (positional plagiocephaly)

Fear of aspiration or choking

All of the above

The appropriate time to deliver SIDS risk-reduction recommendations to parents is: (Value: 1 point)

Within the first 24 hours following delivery

During pregnancy

At well-baby visits

All of the above

The subject material was of interest to me.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker John McGrath, Ph.D. was well prepared.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker John McGrath, Ph.D. was easy to understand.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker John McGrath, Ph.D. kept my attention with active participation strategies.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to define SIDS including: etiology, risk factors, and epidemiology.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to list the critical SIDS risk-reduction messages for parents/caregivers.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to list four barriers to infant back sleeping for parents/caregivers.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to describe the pharmacist’s key role as an educator to parents/caregivers and peers about SIDS.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The audiovisuals conveyed information in a manner that was easy to understand.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

Overall, the information presented on The Pharmacist’s Role in Sudden Infant Death Syndrome (SIDS) Risk Reduction was:

Too Easy

Somewhat Easy

Just Right

Somewhat Difficult

Too Difficult

Did you attend the DDMAC lecture?

Yes

No (Click Continue to go to the next section)

DDMAC has jurisdiction over all prescription and OTC product advertising (Value: 1 point)

True

False

For non-subpart H submissions, drug sponsors are required to submit promotional materials to DDMAC for pre- clearance prior to disseminating the promotional materials (Value: 1 point)

True

False

Drug sponsors are required to submit promotional materials to DDMAC upon disseminating the promotional materials (Value: 1 point)

True

False

Prescription drug promotion: (Value: 1 point)

Must not be false or misleading

Must have fair balance

Must be supported by substantial evidence

All of the above

Which of the following is/are true of DTC advertising: (Value: 1 point)

Reminder ads are not allowed on television

The television commercial must be reviewed by the FDA

Risk information must be presented in the commercial if the benefits are discussed

All of the above are true

The subject material was of interest to me.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Barbara S. Chong, Pharm.D., BCPS was well prepared.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Barbara S. Chong, Pharm.D., BCPS was easy to understand.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Barbara S. Chong, Pharm.D., BCPS kept my attention with active participation strategies.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to define DDMAC's role including: advisories and enforcement actions.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to discuss which regulations in the Federal Food, Drug, and Cosmetic Act and Code of Federal Regulations that most pertain to DDMAC.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to describe the differences between help seeking/disease awareness, coming soon, institutional, reminder, and full product promotional materials.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to discuss common violations in promotional materials such as broadening of indication, omission of material facts, minimization or risk, unsubstantiated superiority, an overstatement of efficacy.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

Overall, the information presented on Division of Drug Marketing, Advertising, and Communications perspective on regulating and promotion of prescription drugs was:

Too Easy

Somewhat Easy

Just Right

Somewhat Difficult

Too Difficult

Did you attend the Antiretroviral Therapy lecture?

Yes

No (Click Continue to go to the next section)

Maraviroc, Selzentry™, is indicated for the treatment of which group of HIV-positive individuals? (Value: 1 point)

Treatment-naïve patients

CXCR4-tropic patients, treatment-experienced patients

CCR5-tropic, treatment-experienced patients

Dual-tropic, treatment-experienced patients

Raltegravir, Isentress™, belongs to which class of antiretrovirals? (Value: 1 point)

Integrase Inhibitors

CCR5-Inhibitors

Protease Inhibitors

Non-nucleoside Reverse Transcriptase Inhibitors

Raltegravir plasma concentrations significantly decrease when combined with which medication? (Value: 1 point)

Ritonavir

Acetaminophen

Midazolam

Rifampin

Etravirine is indicated for which HIV-infected group of patients? (Value: 1 point)

Treatment-naïve patients

Treatment-experienced patients

CXCR-tropic, treatment-naïve patients

CCR5-tropic, treatment-naïve patients

Etravirine belongs to the non-nucleoside reverse transcriptase inhibitor class. (Value: 1 point)

True

False

The subject material was of interest to me.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Kristin Busse, Pharm.D.was well prepared.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Kristin Busse, Pharm.D.was easy to understand.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Kristin Busse, Pharm.D.kept my attention with active participation strategies.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to identify novel antiretrovirals recently approved by the FDA.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to identify clinically significant drug interactions with recently approved antiretrovirals.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to recommend appropriate antiretroviral therapy for treatment-experienced patients with multiple resistance mutations.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

Overall, the information presented on HIV Antiretroviral Update 2008 was:

Too Easy

Somewhat Easy

Just Right

Somewhat Difficult

Too Difficult

Did you attend the Multidrug resistant gram-negative organisms lecture

Yes

No (Click Continue to go to the next section)

All of the following antibiotics could be used to treat an infection caused by Pseudomonas aeruginosa except: (Value: 1 point)

Ertapenem

Meropenem

Imipenem/cilastatin

Doripenem

Colistin

Which of the following best describes the mechanism of action of Colistin: (Value: 1 point)

Binds exclusively to the 50S ribosomal subunit

Inhibits DNA gyrase

Inhibits cell wall synthesis by binding to penicillin binding proteins (PBPs)

Inhibits folic acid reduction to tetrahydrofolate

Binds to phospholipids, alters permeability, and damages the cell membrane permitting leakage of intracellular contents

Which of the following is the most reported adverse event caused by Colistin? (Value: 1 point)

Rash

Nephrotoxicity

Hepatotoxicity

Nausea and Vomiting

Thrombocytopenia

Which of the following compounds has activity against Acinetobacter baumannii? (Value: 1 point)

Clavulanic acid

Cilastatin

Sulbactam

Tazobactam

Which of the following statements are FALSE in regards to new antibiotic development? (Value: 1 point)

Antibiotics have a weak return on investment

Only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and only one of these five is approved

According to a recent FDA report, bringing a new drug to market can cost $800 million to $1.7 billion

The median time from the beginning of clinical testing through FDA review for new antibiotics and similar drugs was just over six years

The pharmaceutical industry views antibiotic development as low risk

The subject material was of interest to me.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Tim Jancel, Pharm.D. was well prepared.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Tim Jancel, Pharm.D. was easy to understand.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The speaker Tim Jancel, Pharm.D. kept my attention with active participation strategies.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to discuss the emerging prevalence and etiology of resistant gram-negative bacilli and their impact on the clinical spectrum of nosocomial infections.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to describe the various mechanisms of resistance that lead to MDR Gram-negative bacilli.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to describe the selection of antimicrobials for serious gram-negative infections, including the use of novel antimicrobial strategies.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to list two approaches that have been used to take advantage of pharmacokinetics and pharmacodynamics of antimicrobials.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to list two strategies and two barriers to antimicrobial stewardship.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The session effectively enabled me to discuss the reasons that have led to limited antimicrobial development.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The audiovisuals conveyed information in a manner that was easy to understand.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

Overall, the information presented on Treatment of Multidrug Resistant Gram-negative Organisms was:

Too Easy

Somewhat Easy

Just Right

Somewhat Difficult

Too Difficult

This program, 2008 NIH Pharmacotherapy Frontiers, has given me a chance to enhance my professional growth.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The overall program goals were met.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

The facility was comfortable and conducive to learning.

Strongly Disagree

Disagree

Cannot Decide

Agree

Strongly Agree

Please give us suggestions for areas of pharmacotherapy you would like addressed in future Pharmacotherapy Frontiers symposia?